On July 25, 2025, Larry Wood, Edwards Lifesciences' corporate vice president and group president of transcatheter aortic valve replacement (TAVR) and surgical structural heart, departed the company. Wood, who was instrumental in building Edwards' TAVR business, has taken on the role of Chief Executive Officer at Procept BioRobotics.
Wood's departure marks a significant executive change for Edwards Lifesciences, as he played a key role in the development and commercial success of its leading TAVR platform. His leadership was central to the company's strategy in this critical segment.
The company will now need to manage the transition in leadership for its TAVR and surgical structural heart divisions. Investors will be watching for announcements regarding Wood's successor and any potential shifts in strategy for these important business areas.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.